Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × cemiplimab × Clear all

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Multiple Myeloma